Top Story Today
A Drug That Destroys Cancer Proteins (Instead of Just Blocking Them) Just Got FDA Approval
The FDA approved vepdegestrant, the first-ever PROTAC approved for ER+/HER2-negative/ESR1-mutated advanced or metastatic breast cancer, validating an entirely new mechanism that hijacks a cell's own recycling machinery to destroy cancer-driving proteins rather than merely blocking them. The daily pill more than doubled progression-free survival versus the old injectable standard. Every biotech working on protein degradation just got a massive credibility boost.
Why it matters: PROTACs have attracted billions in investment over the past decade on the promise of destroying, not just inhibiting, disease-causing proteins. This first approval transforms the field from theoretical to proven, with implications stretching far beyond breast cancer to targets like KRAS, androgen receptor, and more.
Read more →Clinical & Regulatory
FDA's Biologics Gatekeeper Walked Out. Again.
CBER just lost another director. Vinay Prasad departed April 30, leaving the center that approves gene therapies, CAR-T treatments, and vaccines in the hands of yet another acting director. Analysts expect 6 to 12 months of regulatory volatility, with some sponsors facing potential 12- to 24-month setbacks if new requirements get imposed on previously agreed trial designs.
Read more →Summit Was Supposed to Dethrone Keytruda. Then the Data Arrived.
Summit Therapeutics' stock cratered 25% after its ivonescimab trial missed an interim endpoint in squamous lung cancer. The company licensed the bispecific antibody from Akeso for $500 million upfront (up to $5 billion in milestones), positioning it as a Keytruda killer. Full trial data is still expected later in 2026, but "just wait" is a tough pitch after losing a quarter of your market cap.
Read more →The FDA Just Slammed the Door on Cheap Liraglutide
The FDA proposed keeping liraglutide off the 503B Bulks List, which would block compounding pharmacies from producing cheaper versions of Saxenda at scale. Combined with similar exclusions for semaglutide and tirzepatide, the agency is effectively trying to shut down the entire compounded GLP-1 market. Comments are open until June 29.
Read more →Funding & Financings
Hemab Doubled on Day One. Rare Blood Diseases Are Wall Street Catnip.
Hemab Therapeutics raised $301.5 million in a 27% upsized IPO, then watched shares surge 89% on day one. The Danish-American biotech is developing bispecific antibodies for rare bleeding disorders, with Breakthrough Therapy Designation already in hand for its lead candidate. Its Novo Nordisk and Genmab pedigree didn't hurt either.
Read more →The Brain Drug Startup That Convinced Wall Street to Bet $255M on Crazy
Neuropsychiatry drugs fail roughly 80-85% of the time, yet Seaport Therapeutics just raised $255 million in the first brain-focused biotech IPO of 2026. Karuna Therapeutics co-founder Daphne Zohar (whose last company sold for $14 billion) is back with a platform that redesigns known brain compounds for better oral absorption. Shares popped 10% on debut.
Read more →Deals & Strategy
Viking's Obesity Blockbuster Just Got a Legal Problem
Ligand Pharmaceuticals moved to terminate its decade-old partnership with Viking Therapeutics, alleging Viking got so focused on its blockbuster obesity drug (VK2735, with two fully enrolled Phase 3 trials) that it abandoned the thyroid hormone programs it licensed in 2014. Ligand wants the drugs back. Viking is disputing the termination. Expect litigation.
Read more →The Biggest Clinical Trial Land Grab You Didn't See Coming
FOMAT Medical Research acquired Topography Health's site business to become America's largest embedded research organization, with 35+ sites across six states. The bet: plugging clinical trials into community doctor's offices (instead of remote academic centers) can fix an industry where 11% of trial sites fail to enroll a single patient.
Read more →Two Oxford Companies Think Your Genes Hold the Key to Autoimmune Disease
Genomics Ltd. and Greywolf Therapeutics are teaming up to mine massive gene datasets for autoimmune drug targets, focusing on ERAP enzymes linked to conditions like spondyloarthritis and psoriatic arthritis. Drug targets backed by genetic evidence are more than twice as likely to succeed in trials, making this a classic de-risking play.
Read more →